Immunai, an AI-driven biotech company based in Israel, has entered into a significant discovery collaboration with Boehringer Ingelheim, a major German pharmaceutical firm. This partnership is valued at up to $15 million and is scheduled to continue through 2027.
The collaboration will leverage Immunai's advanced single-cell AI platform to analyze T cells from a vast array of patient samples related to cancer and autoimmune diseases. The goal is to uncover common patterns of T-cell dysfunction that could lead to new therapeutic targets. Promising candidates identified during this analysis will undergo further validation through functional perturbation and laboratory experiments conducted at Immunai's facility in New York.
Notably, this partnership aims to bridge the gap between cancer immunology and autoimmune research, areas that have traditionally been studied in isolation. Noam Solomon, Ph.D., CEO of Immunai, emphasized the significance of this integrated approach, suggesting that insights gained could enhance understanding and treatment strategies across both fields.
This collaboration underscores the growing trend of utilizing AI in drug discovery, particularly in the life sciences sector, where the ability to analyze complex biological data can lead to innovative solutions for challenging health issues. As the project progresses, there may be opportunities for Boehringer Ingelheim to expand their involvement based on the scientific outcomes achieved.